Disclaimer: This article is educational content for athletes, coaches, and studio professionals. It is not medical advice, a diagnosis, or guidance to start, stop, or change any medication. Dosing and treatment decisions belong with a licensed clinician. Always talk to a clinician about individual care.
GLP-1 receptor agonists (and related dual agonists) have moved from specialty clinics into everyday gym conversations. Clients ask about hunger that suddenly drops, clothes that fit differently in weeks, and whether their program still makes sense. Coaches need a clear mental model: what these medicines do physiologically, what trials actually measured, and where coaching ends and clinical care begins.
What “GLP-1” means in plain language
GLP-1 (glucagon-like peptide-1) is an incretin hormone involved in glucose regulation and appetite signaling. Medicines in this class mimic or amplify that pathway. In practice, many people notice lower appetite, earlier fullness, and substantial weight reduction when therapy is clinically indicated and supervised. That weight change is usually mostly fat, but not only fat. Body-composition trials and reviews matter for coaches because performance, recovery, and long-term metabolic rate track with lean tissue and function, not scale weight alone.
The American Diabetes Association’s Standards of Care discuss obesity pharmacotherapy in a dedicated section and emphasize comprehensive care, including nutrition and muscle-preserving strategies as part of responsible management. See the ADA Standards of Care 2026 (obesity section) and doi:10.2337/dc26-s008.
Why coaches are suddenly in the conversation
Three coaching realities show up repeatedly:
- Appetite and session fueling change. Lower hunger can help adherence for some, yet it can also make pre- and post-training eating feel effortful. That is a coaching and habits problem, not a reason to invent medical rules.
- The scale moves faster than strength. Rapid weight loss can look like “success” while bar speed, volume tolerance, or stairs feel worse. Body composition and function deserve equal attention.
- Clients want certainty you cannot give. Coaches can share education and training structure. They cannot prescribe, dose, or promise outcomes tied to a specific drug.
What large trials tell us about weight and composition
Registration trials such as STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) showed large average weight reductions relative to lifestyle alone. Body-composition substudies using DXA reported that a meaningful share of lost weight was lean mass, not only fat. A Circulation primer on muscle and GLP-1 receptor agonists summarizes that debate and discusses whether muscle changes look adaptive or concerning depending on context, age, and measurement method. See Neeland et al., Circulation.
In commonly cited DXA summaries discussed in that muscle-and-GLP-1 literature, lean mass accounted for roughly 45% of the weight lost in a STEP-1 body-composition analysis and roughly 26% in a SURMOUNT-1 analysis (fractions of total weight change attributed to lean mass). Those figures are averages from trial substudies, not guarantees for any individual athlete. Lean mass on DXA is not identical to contractile skeletal muscle. It includes water, organs, and other non-fat tissue. Interpreting “muscle loss” from a single lean-mass number alone is incomplete. See Neeland et al., Circulation.
Newer real-world style data: SEMALEAN
The SEMALEAN study (doi:10.1111/dom.70141) followed people with obesity treated with semaglutide 2.4 mg and tracked weight, DXA composition, and handgrip strength over about a year. Mean weight fell on the order of 10% by month 7 and about 13% by month 12, with larger relative fat-mass reductions. Lean mass declined early (about 3 kg by month 7 in the reported cohort) and then stabilized, while handgrip strength improved on average by about 4.5 kg at month 12, and the share of people classified with sarcopenic obesity decreased. That pattern is a useful coaching reminder: mass and function can move in different directions. Strength and daily function metrics belong on the dashboard next to body weight.
What is still being studied: resistance training and protein
Sports nutrition consensus outside GLP-1 care already favors progressive resistance training and adequate protein during energy deficits to support lean tissue and performance. Whether those same tools reliably preserve muscle during modern GLP-1 based weight loss is an active research question, not a settled product claim.
The LEAN-PREP protocol (BMJ Open) describes an ongoing randomized trial (also listed as ClinicalTrials.gov NCT06885736) testing pragmatic resistance exercise and/or higher protein intake (targeting about 1.6 g per kg per day in the protocol design) during semaglutide or tirzepatide therapy, with MRI quadriceps area as a primary outcome. Protocol papers are not proof. They show what researchers consider plausible, testable strategies. Coaches can treat resistance training plus thoughtful protein distribution as reasonable, evidence-informed habits aligned with general sports nutrition, while waiting for definitive GLP-1 specific trial results.
A coaching framework that stays inside your lane
1. Separate clinical goals from gym goals
Clinical teams manage indications, contraindications, titration, side effects, and stop or switch decisions. Coaches manage progressive overload, skill practice, recovery load, and food logistics the client can actually execute. When a client reports nausea, dizziness, or unexplained weakness, the right move is referral back to the clinician, not program heroics.
2. Track function, not only kilograms
Useful non-medical markers include estimated 1RM or reps-in-reserve trends, stair or walk pace, sit-to-stand quality, grip if you have a dynamometer, session RPE, and how clothes and training photos change. SEMALEAN’s handgrip improvement alongside lean-mass change is a reminder that function can be preserved or improved even when lean mass shifts. See SEMALEAN study (doi:10.1111/dom.70141).
3. Treat low intake as a programming constraint
If appetite is very low, prioritize protein-forward meals the client still tolerates, keep hard intervals and maximal lifting volume realistic, and emphasize sleep and easy steps. This is sports-nutrition pragmatism, not a GLP-1 specific protocol.
4. Watch higher-risk profiles more carefully
Older adults, people with low baseline strength, long inactivity, or prior large weight cycling may have less reserve. The Circulation discussion of adaptive versus concerning muscle change explicitly flags age and prefrailty as contexts that need careful candidate selection and monitoring. See Neeland et al., Circulation. Coaches should collaborate early with clinical teams for these clients.
Practical training notes (general sports guidance)
None of the following is a proven “GLP-1 cure” for lean-mass loss. It is standard coaching hygiene during any substantial weight-loss phase:
- Keep 2 to 4 weekly resistance sessions covering major patterns (squat or sit-to-stand variants, hinge, push, pull, carry) at loads the client can recover from.
- Progress load or reps when technique and recovery allow. Rapid weight loss is not a free pass to abandon progressive overload.
- Distribute protein across the day in amounts the client can digest. Many sports-nutrition reviews discuss roughly 1.6 g/kg/day as a common target range during deficits for trained adults, which is also the intake target being tested in LEAN-PREP. Individual needs vary. Clinical dietitians should guide medically complex cases. See LEAN-PREP protocol (BMJ Open).
- Reassess every 4 to 8 weeks: strength trends, energy, GI comfort around training, and whether the schedule is still realistic.
What coaches should not do
- Do not recommend starting, stopping, splitting, or “timing” injections.
- Do not diagnose sarcopenia or metabolic disease from gym screens alone.
- Do not sell pharmacy affiliates or imply that a supplement stack replaces clinical care.
- Do not promise that lifting will fully cancel lean-mass loss. Trials and reviews show heterogeneity. See Neeland et al., Circulation and SEMALEAN study (doi:10.1111/dom.70141).
How FITsociety thinks about the topic
GLP-1 medicines are clinical tools. Training and protein habits are lifestyle tools. The overlap is where good coaching earns its keep: helping people keep moving well, eating enough of the right things, and measuring what matters while clinicians manage the prescription. ADA materials stress comprehensive obesity care rather than medication in isolation. See ADA Standards of Care 2026 (obesity section).
If you coach someone on therapy, ask for permission to coordinate with their clinician or dietitian, document functional baselines, and keep education humble. The strongest professional position is curiosity plus boundaries.
